Collaboration and Licensing Revenue (Tables)

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following table summarizes the amounts recorded as revenue from continuing operations in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2019, 2018 and 2017.

	Year Ended December 31,
	2019			2018		2017
ZIOPHARM Oncology, Inc.	$	2,171		$	16,298	$	69,812
Ares Trading S.A.	—			11,175		10,738
Oragenics, Inc.	(564		)	1,353		1,469
Intrexon T1D Partners, LLC	—			2,502		5,968
Intrexon Energy Partners, LLC	2,596			6,929		10,665
Intrexon Energy Partners II, LLC	1,217			2,998		3,672
Fibrocell Science, Inc.	3,713			1,394		7,344
OvaXon, LLC	—			—		1,966
S & I Ophthalmic, LLC	—			—		755
Harvest start-up entities (1)	4,862			14,447		15,232
Other	64			12,444		7,003
Total	$	14,059		$	69,540	$	134,624

(1) For the years ended December 31, 2019, 2018, and 2017, revenue recognized from collaborations with Harvest start-up entities include Exotech Bio, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. For the years ended December 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities also include Genten Therapeutics

and CRS Bio. For the year ended December 31, 2017, revenue recognized from collaborations with Harvest start-up entities also include Relieve Genetics.

Summary of Deferred Revenue

Deferred revenue from continuing operations consists of the following:

	December 31,
	2019		2018
Collaboration and licensing agreements	$	50,593	$	54,323
Prepaid product and service revenues	2,805		2,933
Other	435		560
Total	$	53,833	$	57,816
Current portion of deferred revenue	$	5,697	$	11,088
Long-term portion of deferred revenue	48,136		46,728
Total	$	53,833	$	57,816

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue from continuing operations associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of December 31, 2019 and 2018, including the estimated remaining performance period as of December 31, 2019.

	Average Remaining Performance Period (Years)	December 31,
		2019		2018
ZIOPHARM Oncology, Inc.	0.0	$	—	$	1,214
Oragenics, Inc.	4.4	2,864		1,785
Intrexon Energy Partners, LLC	4.2	8,362		10,267
Intrexon Energy Partners II, LLC	4.9	12,843		14,060
Fibrocell Science, Inc.	4.9	17,697		17,519
Harvest start-up entities (1)	5.2	6,993		7,644
Other	2.8	1,834		1,834
Total		$	50,593	$	54,323

(1)

As of December 31, 2019 and 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes Exotech Bio, AD Skincare, and Thrive Agrobiotics.